

There is not a direct correlation between the Ridley-Jopling classification and the WHO classification. Thus, it is erroneous to state that all BT patients should be classified as PB. This would depend upon the findings in the specific patient. In addition, they state that slit-skin smears were done “. . . from six routine sites in all patients and selected sites in some patients.” They do not state how many patients did not have slit-skin smears prepared from lesions. In patients toward the tuberculoid end of the leprosy spectrum, classifying the patient as PB without doing slit-skin smears from lesions may give erroneous results. A WHO Expert Committee report states: “Skin smears should be taken from a minimum of three sites, including one earlobe and two representative active skin lesions. In paucibacillary patients, if there is only a single skin lesion, the two smears may be taken from its active edge at sites diametrically opposite to each other.”⁽¹⁾ The same WHO publication briefly discusses the difficulty in classifying borderline tuberculoid patients with multiple macular lesions. The report states: “Classification of these patients should therefore be undertaken only after

careful consideration of all clinical features.”⁽²⁾ In order to deal with the problem of classifying such patients, a subsequent WHO publication recommends that any patient who has more than five skin lesions and any patient who has more than one nerve trunk involved be classified as multi-bacillary⁽³⁾. Thus, it is unclear how many of the 21 patients in the Ebenezer paper in fact have paucibacillary leprosy.

—Richard I. Frankel, M.D., M.P.H.

*Professor of Medicine
University of Hawaii at Manoa
1356 Lusitana Street
Honolulu, Hawaii 96813-2427, U.S.A.*

REFERENCES

1. WHO Expert Committee on Leprosy. Sixth report. Geneva: World Health Organization, 1988, p. 17. Tech. Rep. Ser. 768.
2. WHO Expert Committee on Leprosy. Sixth report. Geneva: World Health Organization, 1988, p. 16. Tech. Rep. Ser. 768.
3. World Health Organization. A guide to eliminating leprosy as a public health problem. 1st edn. Geneva: World Health Organization, 1995, p. 21. WHO/LEP/95.1.

Dr. Ebenezer Replies

TO THE EDITOR:

Professor Richard I. Frankel's comments on our paper entitled “Multibacillary nerve histology in clinically diagnosed borderline tuberculoid leprosy patients,” which appeared in the September 1996 issue of the INTERNATIONAL JOURNAL OF LEPROSY, has given us an opportunity to restate our opinion.

All patients in our study had either five skin lesions or less. Only borderline tuberculoid patients who had an obvious cutaneous nerve enlargement were selected, and none had any nerve trunk enlargement. Inadvertently, this information was not presented in our manuscript. Out of the 21 patients selected, 1 was skin-smear positive for acid-fast bacilli (AFB) and skin biopsies from 2 and nerve biopsies from 10 showed AFB with borderline lepromatous histology.

In practice, most programs use clinical criteria for classifying and deciding the ap-

propriate treatment regimen for individual patients, particularly in view of the non-availability or non-dependability of skin-smear services⁽¹⁾. Therefore, irrespective of the skin smear, clinically grouping such patients as paucibacillary may inappropriately include a significant number of patients having multibacillary leprosy.

—Gigi J. Ebenezer, M.B.B.S., M.D.

*Head, Department of Histopathology
Schieffelin Leprosy Research
and Training Center
Karigiri 632 106
North Arcot District
Tamil Nadu, India*

REFERENCES

1. World Health Organization. A guide to eliminating leprosy as a public health problem. 1st edn. Geneva: World Health Organization, 1995, p. 20. WHO/LEP/95.1.